Data / Form D filings / ImmunoGenesis, Inc.
ImmunoGenesis, Inc.: Form D filings
ImmunoGenesis, Inc., a biotechnology company in Doylestown, PA, filed 2 Form D notices with the SEC between 2024 and 2025. The latest, on January 15, 2025, reports $5.7 million sold of a $25 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 263 North Main St., Apt 417, Doylestown, PA, 18901
- Phone
- (346) 772-0336
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2018057
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | New notice | $24,999,999 | $5,749,998 | $19,250,001 | 2 | Dec 18, 2024 | sec.gov |
| Apr 3, 2024 | New notice | $66,531,095 | $44,426,112 | $22,104,983 | 88 | Mar 18, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael A. Curran | Director | |
| Ted Koutouzis | Director | |
| Jennifer Barlow | Executive Officer, Director | |
| Robert B. Stein | Director | |
| Clifford B. Stocks | Director | |
| Thomas A. Barton | Director |
Other biotechnology companies in Pennsylvania that filed recently
- BioLattice Ophthalmics, Inc, $1.8 million · Oct 28, 2026
- Myris Therapeutics, Inc. $500,000 · Oct 14, 2026
- Praeventix, Inc. $5.6 million · Sep 10, 2026
- Plowshare Therapies LLC $6.7 million · Aug 31, 2026
- Noveome Biotherapeutics, Inc. $6.8 million · Aug 27, 2026
- AlloTRx Bio Inc. $500,000 · Aug 24, 2026
Every Form D from the week of Jan 13, 2025 · All recent filings in Pennsylvania · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ImmunoGenesis, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.